Drugs and FDA

FDA approves asundexian pill to prevent recurrent strokes

The FDA approved daily asundexian with antiplatelet therapy for certain people who recently had an ischemic stroke or transient ischemic attack.

Reported by 2 outlets Sunday, November 15, 2026

Pink tablets in a blister pack
Photo: CC0

The FDA approved asundexian, sold as Sunharbo, to reduce the risk of another stroke in certain adults who recently had an ischemic stroke or transient ischemic attack. The daily 50 mg pill is taken with antiplatelet therapy, such as aspirin. Fox News reported it is not for people whose strokes were caused by a heart-related clot.

In a Phase 3 randomized trial involving 12,327 patients across 37 countries, people who took asundexian with antiplatelet therapy had a 26% relative reduction in ischemic stroke compared with those who took placebo with the therapy. The treatment period was 14.2 months, according to Fox News.

The reports differ on bleeding findings. Time said Bayer’s data showed no significant increase in bleeding events. Fox News reported gastrointestinal bleeding was more common with asundexian, and major bleeding increased among patients older than 75 during the first 90 days. The reports said the trial findings were published in The New England Journal of Medicine on Nov. 9.

Reporting on this story

More top stories

This Week in Medicine

The week in medicine, in five minutes

The most important medical news of the week, summarized for you and easy to read. Every Sunday, free.

Free. No spam. Unsubscribe anytime.